Table of Content

1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview

3. Market Dynamics
3.1. Market Definition
3.2. Key Drivers
3.2.1. Rising Geriatric Population
3.2.2. Surge In The Prevalence Of Rheumatoid Arthritis Disease
3.2.3. Growing Healthcare Expenditure
3.3. Key Restraints
3.3.1. Patent Expirations
3.3.2. Lack Of Regulatory Guidelines For Biosimilars Will Delay Their Availability In Some Regions
3.3.3. Less Expensive Alternatives

4. Key Analytics
4.1. Porter’S Five Force Analysis
4.1.1. Threat Of New Entry
4.1.2. Threat Of Substitution
4.1.3. Buyer’S Power
4.1.4. Supplier’S Power
4.1.5. Competitive Rivalry
4.2. Etiology Of Rheumatoid Arthritis (Ra)
4.3. Symptoms Of Rheumatoid Arthritis
4.4. Risk Factors Associated With Rheumatoid Arthritis
4.5. Opportunity Matrix
4.6. Vendor Landscape
4.7. Key Investment Insights

5. Market By Type
5.1. Prescription-Based Drugs
5.2. Over-The-Counter Drugs

6. Market By Drug Class
6.1. Disease Modifying Anti-Rheumatic Drugs
6.2. Nonsteroidal Anti-Inflammatory Drugs
6.3. Corticosteroids
6.4. Uric Acid Drugs
6.5. Other Drug Class

7. Geographical Analysis
7.1. North America
7.1.1. The United States
7.1.2. Canada

8. Company Profiles
8.1. Abbott Laboratories
8.2. Abbvie Inc
8.3. Amgen Inc
8.4. Becton, Dickinson & Company (Bd)
8.5. Bio-Rad Laboratories Inc
8.6. Bristol-Myers Squibb Company
8.7. Eli Lilly & Company
8.8. Lupin Limited
8.9. F. Hoffmann-La Roche
8.10. Johnson & Johnson
8.11. Merck & Co Inc
8.12. Novartis Ag
8.13. Perkinelmer
8.14. Pfizer Inc
8.15. Ucb



List of Figures


List of Figures


Figure 1: Porter’S Five Force Analysis
Figure 2: Opportunity Matrix
Figure 3: Vendor Landscape
Figure 4: Key Investment Insights
Figure 5: North America Anti-Rheumatics Market, By Type, In 2019
Figure 6: North America Anti-Rheumatics Market, By Prescription-Based Drugs, 2020-2028 (In $ Million)
Figure 7: North America Anti-Rheumatics Market, By Over-The-Counter Drugs, 2020-2028 (In $ Million)
Figure 8: North America Anti-Rheumatics Market, By Drug Class, In 2019
Figure 9: North America Anti-Rheumatics Market, By Disease Modifying Anti-Rheumatic Drugs, 2020-2028 (In $ Million)
Figure 10: North America Anti-Rheumatics Market, By Nonsteroidal Anti-Inflammatory Drugs, 2020-2028 (In $ Million)
Figure 11: North America Anti-Rheumatics Market, By Corticosteroids, 2020-2028 (In $ Million)
Figure 12: North America Anti-Rheumatics Market, By Uric Acid Drugs, 2020-2028 (In $ Million)
Figure 13: North America Anti-Rheumatics Market, By Other Drug Class, 2020-2028 (In $ Million)
Figure 14: North America Anti-Rheumatics Market, Country Outlook, 2019 & 2028 (In %)
Figure 15: The United States Anti-Rheumatics Market, 2020-2028 (In $ Million)
Figure 16: Canada Anti-Rheumatics Market, 2020-2028 (In $ Million)


List of Tables


List of Tables


TABLE 1: MARKET SNAPSHOT - ANTI-RHEUMATICS
TABLE 2: COMMON SYMPTOMS OF RHEUMATOID ARTHRITIS
TABLE 3: RISK FACTORS FOR RHEUMATOID ARTHRITIS
TABLE 4: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 5: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 6: NORTH AMERICA PRESCRIPTION-BASED DRUGS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 7: NORTH AMERICA PRESCRIPTION-BASED DRUGS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 8: NORTH AMERICA OVER-THE-COUNTER DRUGS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 9: NORTH AMERICA OVER-THE-COUNTER DRUGS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 10: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY DRUG CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 11: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY DRUG CLASS, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 12: NORTH AMERICA DISEASE MODIFYING ANTI-RHEUMATIC DRUGS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 13: NORTH AMERICA DISEASE MODIFYING ANTI-RHEUMATIC DRUGS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 14: NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 15: NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 16: NORTH AMERICA CORTICOSTEROIDS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 17: NORTH AMERICA CORTICOSTEROIDS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 18: NORTH AMERICA URIC ACID DRUGS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 19: NORTH AMERICA URIC ACID DRUGS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 20: NORTH AMERICA OTHER DRUG CLASS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 21: NORTH AMERICA OTHER DRUG CLASS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
TABLE 22: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 23: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)